GHRS: GH Research PLC
Performance
GHRS +42.67%
Watchlist
Select an item
Summary
GHRS at a glance
GHRS returned +42.67% over the past year and -4.57% a year over five years. Its worst drop in that year was -41.02%, smaller than 36% of stocks on Redstone, and its Sharpe ratio of 0.80 beats 66% of stocks on Redstone. It pays no dividends.
Current Drawdown
-37.14%
Rolling Volatility
57.81%
Actions
Metrics
Risk Indicators
Alpha42.14%
Beta1.37x
Sharpe0.80
Sortino1.31
Omega1.15
Calmar1.04
Martin3.49
Profile
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression.
- Sector
- Health Care
- Market cap
- $1.3B
- Listed
- Jun 2021
- Employees
- 73
- Website
- ghres.com
Comparisons